Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test predict clot risk in PCOS?

NCT ID NCT06339567

Knowledge-focused Sponsor: Fondation Hôpital Saint-Joseph Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This study looks at whether different types of polycystic ovary syndrome (PCOS) have different blood clotting profiles. Researchers will measure several biological markers in blood samples from women with PCOS and compare them based on the presence of insulin resistance. The goal is to understand if certain PCOS phenotypes are more prone to venous thrombosis, which could help personalize treatment and monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood tests measuring several thrombotic biological markers (C protein, S protein, CRP us, Factor VIII, TFPI, nAPCsr, SHBG, nTMsr)
What this could lead to
If successful, this could help doctors tailor monitoring and contraceptive choices for women with PCOS based on their specific phenotype, potentially reducing the risk of blood clots.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all populations, and the markers measured are only intermediate indicators, not actual clot events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

352 people

The number who actually took part.

Started

Feb 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be between 18 and 35 years of age at the time of inclusion; * Able to give non-opposition * Strong suspicion of PCOS according to 2023 recommendations * Have stopped hormonal contraception for at least 3 months or insulin-sensitizing treatment for at least 3 months. * Fasting for at least 12 hours. * Be affiliated to a health insurance scheme. * French-speaking Exclusion Criteria: * Already included in a type 1 interventional research protocol (RIPH1). * Be under guardianship or curatorship * Deprived of liberty * Under court protection * Pregnant (positive urine or blood pregnancy test), or within 3 months of post-partum or post abortum, or breastfeeding (or within 3 months of weaning) * Using hormonal contraception or insulin-sensitizing therapy (a wash-out of at least 3 months before inclusion). * Have a personal history of VTE or known thrombophilia. * Current anticoagulant or antiaggregant treatment or treatment stopped less than one month before inclusion. * Have a severe personal medical history in the previous 6 weeks (fracture, infection, hospitalization, surgery, cardiovascular event, cancer).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycystic ovary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycystic ovary syndrome

Contacts and locations

Locations

  • Hôpital Paris Saint Joseph

    Paris, France, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.